

# PHYLOGICA

BREAKTHROUGH PEPTIDE THERAPEUTICS

## Operational update – March Quarter Investor Call

**PERTH, Australia, 30 April 2018:** Phylogica Limited (ASX:PYC) (**Phylogica** or the **Company**), invites shareholders and other interested parties to join a conference call next Monday May 7, accompanying Phylogica's operational update for the March quarter.

Times for the conference call previously lodged contained an error, please find correct details below.

### **Conference Call Details**

Conference call will be held at **11.30am AEST/ 9.30am AWST** on Monday May 7 2018, hosted by CEO Dr Rohan Hockings and CSO Dr Robert Hayes, to discuss activity during the quarter, followed by Q&A with participants.

To submit a question in advance please email your questions to Ben Walsh at [bwalsh@we-buchan.com](mailto:bwalsh@we-buchan.com). To pre-register for the call, with a diary note automatically sent to your calendar, [click here](#).

Conference call ID: **529491**

Country	Dial- in number
Australia:	1 800 558 698
Australian (alternative)	02 9007 3187
New Zealand:	0800 453 055
Hong Kong	800 966 806
Singapore:	800 101 2785
United Kingdom:	0800 051 8245
United States:	(855) 881 1339

**ENDS**

For further information, please contact:

#### INVESTORS

Dr Rohan Hockings  
Phylogica Limited  
[rohanhockings@phylogica.com](mailto:rohanhockings@phylogica.com)

#### MEDIA

Ben Walsh  
WE Buchan  
[bwalsh@buchanwe.com.au](mailto:bwalsh@buchanwe.com.au)  
0411 520 012

### About Phylogica

Phylogica Limited (ASX: PYC) is a biotech company focused on commercialising its intracellular drug delivery platform and screening its Phylomer libraries to identify drug cargoes for development against a wide range of disease targets. Phylogica controls access to the world's most structurally diverse source of peptides called Phylomers, which have the ability to act as effective drug delivery agents, penetrating cell walls to reach previously 'undruggable' targets across a range of disease types, but also drug cargoes.

Phylogica's platform of proprietary cell penetrating peptides is showing promise in delivering a diverse range of drug cargoes into cells with three key *in vivo* proof of concept data packs now demonstrating the diversity and successful intracellular reach of the technology. The company has had collaborations with several pharmaceutical companies including Roche, Medimmune, Pfizer, Janssen and is currently working with Genentech.

### Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Phylogica's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and Phylogica's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. Phylogica undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by Phylogica. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

---

Tel: +61 8 9384 3284 | Fax: +61 8 9284 3801

[www.phylogica.com](http://www.phylogica.com)

**Phylogica Ltd**

ABN 48 098 391 961